论文部分内容阅读
本文报道急黄肝108例服用心肝宝2个月和慢性肝炎32例服用3个月的临床疗效分析,并以一定数量的病例作为对照,对其疗效作出评估。结果急黄肝ALT降至正常达94.4％,胆红素退至正常达98.1％,与对照组比较疗效显著(P<0.05)。对慢性肝炎的白蛋白、浊度和γ—球蛋白异常也有一定的疗效。在HBVM阴转方面。HBsAg阴转率为46.4％。HBeAg阴转率为31.2％。HBcAg阴转度为35.7％。除HBeAg外优于对照组。因此,我们认为心肝宝是一种新的细胞免疫增强剂,具有抗病毒作用。能促进肝细胞的修复,恢复其丄常功能,是治疗病毒性肝炎的新的药物途径。
This article reports the clinical efficacy of 108 cases of acute yellow liver taken 2 months of heart and liver Bao and 32 cases of chronic hepatitis taking 3 months, and a number of cases as a control to assess its efficacy. Results The ALT in acute yellowish liver decreased to 94.4% and bilirubin returned to normal up to 98.1%, which was significantly higher than that in control group (P <0.05). On chronic hepatitis albumin, turbidity and γ-globulin abnormalities also have a certain effect. Negative in the HBVM. The negative conversion rate of HBsAg was 46.4%. The negative rate of HBeAg was 31.2%. HBcAg negative degree of 35.7%. Except HBeAg, it is better than the control group. Therefore, we believe that heart and liver Po is a new cellular immune enhancer, with antiviral effects. Can promote the repair of liver cells, restore its normal function, is a new drug treatment of viral hepatitis.